EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity

Thahani S Habeeb Mohammad, Yash Gupta iD, Cory T Reidl, Vlad Nicolaescu, Haley Gula, Ravi Durvasula, Prakasha Kempaiah iD, Daniel P Becker iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24065120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Thahani S Habeeb Mohammad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Loyola University Chicago, Chicago, IL 60660, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Loyola University Chicago, Loyola University Chicago Stritch School of Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The landscape of viral strains and lineages of SARS-CoV-2 keeps changing and is currently dominated by Delta and Omicron variants. Members of the latest Omicron variants, including BA.1, are showing a high level of immune evasion, and Omicron has become a prominent variant circulating globally. In our search for versatile medicinal chemistry scaffolds, we prepared a library of substituted ɑ-aminocyclobutanones from an ɑ-aminocyclobutanone synthon (11). We performed an in silico screen of this actual chemical library as well as other virtual 2-aminocyclobutanone analogs against seven SARS-CoV-2 nonstructural proteins to identify potential drug leads against SARS-CoV-2, and more broadly against coronavirus antiviral targets. Several of these analogs were initially identified as in silico hits against SARS-CoV-2 nonstructural protein 13 (Nsp13) helicase through molecular docking and dynamics simulations. Antiviral activity of the original hits as well as ɑ-aminocyclobutanone analogs that were predicted to bind more tightly to SARS-CoV-2 Nsp13 helicase are reported. We now report cyclobutanone derivatives that exhibit anti-SARS-CoV-2 activity. Furthermore, the Nsp13 helicase enzyme has been the target of relatively few target-based drug discovery efforts, in part due to a very late release of a high-resolution structure accompanied by a limited understanding of its protein biochemistry. In general, antiviral agents initially efficacious against wild-type SARS-CoV-2 strains have lower activities against variants due to heavy viral loads and greater turnover rates, but the inhibitors we are reporting have higher activities against the later variants than the wild-type (10–20X). We speculate this could be due to Nsp13 helicase being a critical bottleneck in faster replication rates of the new variants, so targeting this enzyme affects these variants to an even greater extent. This work calls attention to cyclobutanones as a useful medicinal chemistry scaffold, and the need for additional focus on the discovery of Nsp13 helicase inhibitors to combat the aggressive and immune-evading variants of concern (VOCs).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19HumansAntiviral AgentsRNA HelicasesMolecular Docking SimulationViral Nonstructural ProteinsDNA Helicases

Stichwörter der Autor:innen

HTSSARantiviralcarbonyl hydratecomputer-aided drug designcoronavirus variantscyclobutanoneenzyme inhibitorhigh-throughput in silico screennonstructural protein 13, Nsp13 helicasepeptidomimeticstransition state mimetic

Substanzen

Antiviral AgentsRNA HelicasesViral Nonstructural ProteinsDNA Helicases

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, Loyola University Chicago, Chicago, IL 60660, USA.
  • Department of Medicine, Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Howard T. Ricketts Laboratory, Department of Microbiology, The University of Chicago, Chicago, IL 60637, USA.

ORCID-Profile: Yash Gupta, Prakasha Kempaiah, Daniel P Becker

Förderung

  • Loyola University Chicago
  • Loyola University Chicago Stritch School of Medicine

Zitieren

APA

Mohammad, T. S. H., Gupta, Y., Reidl, C. T., Nicolaescu, V., Gula, H., Durvasula, R., Kempaiah, P., & Becker, D. P. (2023). In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065120

Vancouver

Mohammad TSH, Gupta Y, Reidl CT, Nicolaescu V, Gula H, Durvasula R, et al. In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065120

BibTeX
@article{Mohammad2023,
  author = {Mohammad, Thahani S Habeeb and Gupta, Yash and Reidl, Cory T and Nicolaescu, Vlad and Gula, Haley and Durvasula, Ravi and Kempaiah, Prakasha and Becker, Daniel P},
  title = {In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24065120}
}
Kostenlos starten →